 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Enrollment open: Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (clinicaltrials.gov) - Oct 13, 2022
P1, N=90, Recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Not yet recruiting --> Recruiting
- ||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
New P1 trial: Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (clinicaltrials.gov) - Aug 26, 2022
P1, N=90, Not yet recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- ||||||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Trial completion, Trial completion date, Trial primary completion date: Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Feb 25, 2022
P3, N=1680, Completed, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Sep 2021
- |||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Trial primary completion date: Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - Feb 25, 2022
P3, N=1200, Recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Sep 2021 Trial primary completion date: Dec 2021 --> May 2026
- |||||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Enrollment open: Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - Jun 3, 2021
P3, N=1200, Recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Trial primary completion date: Dec 2021 --> May 2026 Not yet recruiting --> Recruiting
- |||||||||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
New P3 trial: Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - May 19, 2021
P3, N=1200, Not yet recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- |||||||||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
New P3 trial: Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Jun 11, 2020
P3, N=1680, Recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- |||||||||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
New P3 trial: Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Jun 8, 2020
P3, N=9600, Recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- ||| 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Trial completion: Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Jan 22, 2020
P1, N=90, Completed, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
Enrollment closed: Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Sep 19, 2019
P1, N=90, Active, not recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | 9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech
New P1 trial: Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - Sep 17, 2018
P1, N=90, Not yet recruiting, Sponsor: Shanghai Bovax Biotechnology Co., Ltd.